Search

for
Search:

Research

5 / 556 results

research Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis

7 citations , September 2024 in “The Journal of Dermatology”

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

January 2024 in “American journal of clinical dermatology”

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

research 801 TEC family kinase inhibitors as a novel class of therapeutics in alopecia areata

July 2024 in “Journal of Investigative Dermatology”

ITK inhibitors may effectively treat alopecia areata.

research Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients

December 2025 in “The Journal of Dermatology”

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

research Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial

227 citations , April 2023 in “The Lancet”

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

View more "jak3 tec family kinase inhibitor" in research →

Learn

1 / 801 results

learn Tofacitinib

a JAK inhibitor for alopecia areata and other autoimmune conditions

View more "jak3 tec family kinase inhibitor" in learn →

Experts

6 / 6 results

Clinics

6 / 13 results

All 13 clinic results →

Community Join

— no results

Try a deeper search in community →

Search

for
Search:

Research

research Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis

research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

research 801 TEC family kinase inhibitors as a novel class of therapeutics in alopecia areata

research Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients

research Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial

Learn

learn Tofacitinib

Experts

Jak, 5+ years experience, accredited SMP specialist

Dr. Vimala Manne, MD, MBBS

Dr. Kala Vimal, MD

Vimal, M.B.B.S., M.S., DrNB, ECFMG Certified (USA)

Vimal

Dr. Vimal Kumar, MBBS, MS, DrNB

Clinics

Community Join